Skip to search formSkip to main contentSkip to account menu

VBMCP protocol

Known as: M2 Protocol, VBMCP Regimen, Vincristine-BCNU-Melphalan-Cytoxan-Prednisone Regimen 
A regimen consisting of vincristine, carmustine (BCNU), melphalan, cyclophosphamide, and prednisone used for the treatment of multiple myeloma.
National Institutes of Health

Related topics

Related topics

7 relations
CarmustineCyclophosphamideMelphalanMultiple Myeloma

Broader (1)

M-2 protocol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
A Report on the Research and Development of the e-Bubble Collaboration
The e-Bubble Group aims at building a low-energy neutrino detector with the particular goal of measuring an accurate, real-time… 
2004
2004
New Therapeutic Approaches to Myeloma
Effective treatment for myeloma began in the early 1960s with the introduction of melphalan and cyclophosphamide (1). During the… 
Highly Cited
1999
Highly Cited
1999
The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma
Interferon (IFN) has demonstrated activity in the treatment of patients with multiple myeloma. A previous Eastern Cooperative… 
1984
1984
[Therapy of multiple myeloma. Results of sequential treatment with melphalan-prednisolone and the M2 protocol].
Melphalan and prednisolone were intermittently used for treatment of 101 patients with multiple myeloma. In case of progression… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)